Moving toward the ideal insulin for insulin pumps

被引:26
作者
Cengiz, Eda [1 ]
Bode, Bruce [2 ]
Van Name, Michelle [1 ]
Tamborlane, William V. [3 ]
机构
[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA
[2] Atlanta Diabet Associates, Atlanta, GA USA
[3] Yale Univ, Sch Med, Yale Ctr Clin Invest, New Haven, CT USA
关键词
CGM; closed-loop delivery system; CSII; faster-acting insulin aspart; hyaluronidase; inhaled insulin; pump; site-warming devices; ultra-fast-acting insulin analogs; RAPID-ACTING INSULIN; CONTINUOUS SUBCUTANEOUS INFUSION; RECOMBINANT HUMAN HYALURONIDASE; POSTPRANDIAL GLYCEMIC CONTROL; MULTIPLE DAILY INJECTIONS; REGULAR HUMAN INSULIN; IN-VITRO STABILITY; PHARMACODYNAMIC PROFILES; DIABETES-MELLITUS; INHALED INSULIN;
D O I
10.1586/17434440.2016.1109442
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Advances in insulin formulations have been important for diabetes management and achieving optimal glycemic control. Rapid-acting insulin analogs provide a faster time-action profile than regular insulin and are approved for use in pumps. However, the need remains for therapy to deliver a more physiologic insulin profile. New insulin formulations and delivery methods are in development, with the aim of accelerating insulin absorption to accomplish ultra-fast-acting insulin time-action profiles. Furthermore, the integration of continuous glucose monitoring with insulin pump therapy enables on-going adjustment of insulin delivery to optimize glycemic control throughout the day and night. These technological and pharmacological advances are likely to facilitate the development of closed-loop pump systems (i.e., artificial pancreas), and improve glycemic control and quality of life for patients with diabetes.
引用
收藏
页码:57 / 69
页数:13
相关论文
共 106 条
[1]  
Andersen G, 2014, DIABETES S1, V63
[2]  
[Anonymous], 2014, HUM R REG U 500 CONC
[3]  
[Anonymous], 2015, HUM INS LISPR INJ SU
[4]  
[Anonymous], 2009, NOVOLOG INS ASP RDNA
[5]  
[Anonymous], 2014, APIDRA INS GLUL RDNA
[6]   How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes [J].
Arnolds, S. ;
Kuglin, B. ;
Kapitza, C. ;
Heise, T. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (10) :1415-1424
[7]   Dose-response relationship of insulin glulisine in, subjects with type 1 diabetes [J].
Becker, Reinhard H. A. ;
Frick, Annke D. ;
Nosek, Leszek ;
Heinemann, Lutz ;
Rave, Klaus .
DIABETES CARE, 2007, 30 (10) :2506-2507
[8]  
Bergenstal R, 2009, DIABETES S1, V58
[9]   Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion - A randomized study in type 1 diabetes [J].
Bode, B ;
Raskin, P ;
Weinstein, R ;
Davidson, J ;
Bell, D ;
Henry, R ;
McGill, J ;
Huang, WC ;
Nadeau, D ;
Reinhardt, RR .
DIABETES CARE, 2002, 25 (03) :439-444
[10]  
Bode B, 2015, 75 SCI SESS AM DIAB